Methods of reducing the severity of mucositis

Details Methods of reducing the severity of mucositis Methods of reducing the severity of mucositis

2006-05-15

2010-06-01

Maier, Leigh C (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

07727974

ABSTRACT:
The invention provides methods of reducing the severity of mucositis, involving administration of a toll-like receptor 4 antagonist.

REFERENCES:
patent: 5041427 (1991-08-01), Takayama et al.
patent: 5681824 (1997-10-01), Christ et al.
patent: 5935938 (1999-08-01), Christ et al.
patent: 5952309 (1999-09-01), Rossignol et al.
patent: 6184366 (2001-02-01), Christ et al.
patent: 2003/0130212 (2003-07-01), Rossignol et al.
patent: 2005/0215517 (2005-09-01), Rossignol et al.
patent: WO 00/41703 (2000-07-01), None
patent: WO 01/37843 (2001-05-01), None
patent: WO 01/43691 (2001-06-01), None
patent: WO 01/60382 (2001-08-01), None
patent: WO 01/93921 (2001-12-01), None
patent: WO 03/013440 (2003-02-01), None
patent: WO 03/105861 (2003-12-01), None
Sonis, S. “Mucositis as a biological process . . .” Oral Oncology (1998) vol. 34, pp. 39-43.
Feld, R. “The role of surveillance cultures . . .” Support Care Cancer (1997) vol. 5, pp. 371-375.
Vosika, G. et al “Phase I study of intravenous modified Lipid A” Cancer Immunol. Immunother. (1984) vol. 18, pp. 107-112.
Kwong, K. “Prevention and treatment of oropharyngeal mucositis . . .” Cancer Nursing (2004) vol. 27, No. 3, pp. 183-205.
Kostler, W. et al “Oral mucositis complicating chemotherapy . . .” Cancer J. Clin. (2001) vol. 51, pp. 290-315.
Asea et al., “Novel Signal Transduction Pathway Utilized by Extracellular HSP70,” J. Biol. Chem. 277:15028-15034, 2002.
Chow et al., “Toll-Like Receptor-4 Mediates Lipopolysaccharide-Induced Signal Transduction,” J. Biol. Chem. 274: 10689-10692, 1999.
Christ et al., “E5531, A Pure Endotoxin Antagonist of High Potency,” Science 268:80-83, 1995.
Fort et al., “A Synthetic TLR4 Antagonist Has Anti-Inflammatory Effects in Two Murine Models of Inflammatory Bowel Disease,” J. Immunol. 174:6416-6423, 2005.
Hill et al., “The Primacy of the Gastrointestinal Tract as a Target Organ,” Blood 95:2754-2759, 2000.
Ingalls et al., “Membrane-Associated Proteins of a Lipopolysaccharide-Deficient Mutant ofNeisseria meningitidisActivate the Inflammatory Reponse Through Toll-Like Receptor 2,” Infect. lmmun. 69:2230-2236, 2001.
Lien et al., “A Novel Synthetic Acyclic Lipid A-Like Agonist Activates Cells via the Lipopolysaccharide/Toll Like Receptor 4 Signaling Pathway,” J. Biol. Chem. 276:1873-1880, 2001.
Means et al., “The Biology of Toll-Like Receptors,” Cytokine Growth Factor Rev. 11:219-232, 2000.
Means et al., “Differential Effects of a Toll-Like Receptor Antagonist on Mycobacterium Tuberculosis-Induced Macrophage Responses,” J. Immunol. 166:4074-4082, 2001.
Ohashi et al., “Cutting Edge: Heat Shock Protein 60 is a Putative Endogenous Ligand of the Toll-Like Receptor-4 Complex,” J. Immunol. 164:558-561, 2000.
Sasu et al., “Chlamydia pneumoniaeand Chlamydial Heat Shock Protein 60 Stimulate Proliferation of Human Vascular Smooth Muscle Cells Via Toll-Like Receptor 4 and p44/p42 Mitogen-Activated Protein Kinase Activation,” Circ. Res. 89:244-250, 2001.
Sonis, “A Biological Approach to Mucositis,” J. Support Oncol. 2:21-36, 2004.
Takeuchi et al., “Differential Roles of TLR2 and TLR4 in Recognition of Gram-Negative and Gram-Positive Bacterial Cell Wall Components,” Immunity 11:443-451, 1999.
Zhang et al., “LPS Antagonist E5564 Antagonizes Heat Shock Protein (HSP) 60 and 70 Elicited Innate Immune Activation,” J. Endotoxin Res. 8:201 (Abstract), 2002.
European Search Report, Jun. 25, 2007 (EP Application No. 02757067.0; Search Completed Jun. 15, 2007).
International Search Report from International Application No. PCT/IB2006/003538 dated Jun. 27, 2007.

Affiliated with

Also associated with

Rating

Methods of reducing the severity of mucositis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of reducing the severity of mucositis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of reducing the severity of mucositis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4155290